Hostname: page-component-848d4c4894-ttngx Total loading time: 0 Render date: 2024-05-25T07:20:20.030Z Has data issue: false hasContentIssue false

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

Published online by Cambridge University Press:  15 May 2009

D. Hobson
Department of Medical Microbiology, University of Liverpool
R. L. Curry
Department of Medical Microbiology, University of Liverpool
A. S. Beare
M.R.C. Common Cold Research Unit, Salisbury
A. Ward-Gardner
Medical Department, Esso Refinery, Fawley
Rights & Permissions [Opens in a new window]


Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The intranasal inoculation of volunteers with living partially attenuated strains of influenza A and B viruses offers a new opportunity to determine the protective effect of serum haemagglutin-inhibiting antibody against a strictly homologous virus, under conditions where the time and dosage of the infective challenge can be controlled, the scoring of proven infections can be more precise and higher rates of infection can be achieved than in most natural epidemics.

In 1032 adult volunteers, whose serum HI antibody titre was determined immediately before virus challenge, there was a consistent inverse quantitative relationship between the HI titre and the likelihood of infection. The PD50 (50 % protective dose) of HI antibody was 1/18–1/36, but an unusual finding was that volunteers with no detectable pre-challenge antibody often seem to be less susceptible to infection than those with pre-challenge antibody in low titre.

In one group of volunteers challenged with an influenza B strain there was no evidence that pre-challenge antibody titres against viral neuraminidase had any significant protective effect against challenge infection.

Research Article
Copyright © Cambridge University Press 1972



Allison, A. C. (1965). Genetic factors in resistance against virus infections. Archiv für die gesamte Virusforschung 17, 280.CrossRefGoogle ScholarPubMed
Bashe, W. J., Stegmuller, H., Leonida, D. & Greenwald, P. (1964). Failure of polyvalent vaccine to provide clinical protection against Asian influenza. New England Journal of Medicine 270, 870.CrossRefGoogle ScholarPubMed
Beare, A. S., Hobson, D., Reed, S. E. & Tyrrell, D. A. J. (1968). A comparison of live and killed influenza virus vaccines. Lancet ii, 418.CrossRefGoogle Scholar
Beare, A. S., Maassab, H. F., Tyrrell, D. A. J., Slepushkin, A. N. & Hall, T. S. (1971). A comparative study of attenuated influenza viruses. Bulletin of the World Health Organisation 44, 593.Google ScholarPubMed
Beare, A. S., Tyrrell, D. A. J., Hobson, D., Howells, C. H. L., Pereira, M. S., Pollock, T. M. & Tyler, L. E. (1969). Live influenza B vaccine in volunteers. Journal of Hygiene 67, 1.CrossRefGoogle ScholarPubMed
Downie, J. C. (1970). Neuraminidase-inhibiting and haemagglutination-inhibiting antibodies in serum and nasal secretion of volunteers immunized with attenuated and inactivated influenza B/Eng/13/65 virus vaccines. Journal of Immunology 105, 620.CrossRefGoogle Scholar
Downie, J. C. & Stuart-Harris, C. H. (1970). The production of neutralizing activity in serum and nasal secretion following immunization with influenza B virus. Journal of Hygiene 68, 233.CrossRefGoogle ScholarPubMed
Easterday, B., Laver, W. G., Pereira, H. G. & Schild, G. C. (1969). Antigenic composition of recombinant virus strains produced from human and avian influenza viruses. Journal of General Virology 5, 83.CrossRefGoogle Scholar
Hobson, D., Lane, C. A., Beare, A. S. & Chivers, C. P. (1964). Serological studies on adult volunteers inoculated with oil-adjuvant Asian influenza vaccine. British Medical Journal ii, 271.CrossRefGoogle Scholar
Hoyle, L. (1968). The Influenza Viruses, chap. 27. Vienna: Springer-Verlag.CrossRefGoogle Scholar
Laver, W. G. (1963). The structure of influenza viruses. 3. Disruption of the virus particle and separation of neuraminidase activity. Virology 20, 251.CrossRefGoogle Scholar
Lindenmann, J., Lane, C. A. & Hobson, D. (1963). The resistance of A2G mice to myxoviruses. Journal of Immunology 90, 942.CrossRefGoogle ScholarPubMed
McDonald, J. C., Zuckermann, A. J., Beare, A. S. & Tyrrell, D. A. J. (1962). Trials of live influenza vaccine in the Royal Air Force. British Medical Journal i, 1036.CrossRefGoogle Scholar
McDonald, J. C. & Zuckermann, A. J. (1962). A B O blood groups and acute respiratory virus disease. British Medical Journal ii, 89.CrossRefGoogle Scholar
Maynard, J. E., Dull, H. B., Hanson, M. L., Feltz, E. T., Berger, B. & Hammes, L. (1968). Evaluation of monovalent and polyvalent influenza vaccines during an epidemic of Type A2 and B influenza. American Journal of Epidemiology 87, 148.CrossRefGoogle ScholarPubMed
Meiklejohn, G., Kempe, C. H., Thalman, W. G. & Lennette, E. H. (1952). Evaluation of monovalent influenza vaccines. II. Observations during an influenza A-prime epidemic. American Journal of Hygiene 55, 12.Google ScholarPubMed
Potter, C. W. (1969). HI antibody to various influenza viruses and adenoviruses in individuals of blood groups A and O. Journal of Hygiene 67, 67.CrossRefGoogle ScholarPubMed
Schild, G. C. & Newman, R. W. (1969). Antibody against influenza A2 virus neuraminidase in human sera. Journal of Hygiene 67, 353.CrossRefGoogle ScholarPubMed
Slepushkin, A. N., Schild, G. C., Beare, A. S., Chinn, S. & Tyrrell, D. A. J. (1971). Anti-neuraminidase antibody and resistance to vaccination with live A2/Hong Kong influenza virus vaccines. Journal of Hygiene 69, 571.Google Scholar
Tyrrell, D. A. J. (1963). The use of volunteers. American Review of Respiratory Diseases 88, Supplement 128.Google ScholarPubMed
Webster, R. G. & Laver, W. G. (1967). Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. Journal of Immunology 99, 49.CrossRefGoogle ScholarPubMed
World Health Organization (1953). Expert Committee on Influenza. Technical Report Series of the World Health Organization, no. 64.Google Scholar